Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/PRDX4_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/PRDX4_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PRDX4_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PRDX4_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PRDX4_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PRDX4_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PRDX4_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PRDX4_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00451371 | Breast | DCIS | development of primary sexual characteristics | 29/1390 | 227/18723 | 2.93e-03 | 2.52e-02 | 29 |
GO:00195112 | Breast | DCIS | peptidyl-proline hydroxylation | 5/1390 | 15/18723 | 3.58e-03 | 2.92e-02 | 5 |
GO:00085842 | Breast | DCIS | male gonad development | 20/1390 | 141/18723 | 3.83e-03 | 3.05e-02 | 20 |
GO:00465462 | Breast | DCIS | development of primary male sexual characteristics | 20/1390 | 142/18723 | 4.16e-03 | 3.29e-02 | 20 |
GO:00466612 | Breast | DCIS | male sex differentiation | 22/1390 | 165/18723 | 5.35e-03 | 3.92e-02 | 22 |
GO:005160422 | Breast | DCIS | protein maturation | 34/1390 | 294/18723 | 6.72e-03 | 4.66e-02 | 34 |
GO:000645710 | Endometrium | AEH | protein folding | 61/2100 | 212/18723 | 1.86e-12 | 3.48e-10 | 61 |
GO:000697916 | Endometrium | AEH | response to oxidative stress | 93/2100 | 446/18723 | 1.94e-09 | 1.64e-07 | 93 |
GO:00614589 | Endometrium | AEH | reproductive system development | 88/2100 | 427/18723 | 9.50e-09 | 6.41e-07 | 88 |
GO:00486089 | Endometrium | AEH | reproductive structure development | 87/2100 | 424/18723 | 1.43e-08 | 9.12e-07 | 87 |
GO:009723710 | Endometrium | AEH | cellular response to toxic substance | 34/2100 | 124/18723 | 5.02e-07 | 1.97e-05 | 34 |
GO:199074810 | Endometrium | AEH | cellular detoxification | 30/2100 | 116/18723 | 8.40e-06 | 1.98e-04 | 30 |
GO:00072498 | Endometrium | AEH | I-kappaB kinase/NF-kappaB signaling | 55/2100 | 281/18723 | 2.60e-05 | 4.88e-04 | 55 |
GO:000963610 | Endometrium | AEH | response to toxic substance | 52/2100 | 262/18723 | 2.89e-05 | 5.40e-04 | 52 |
GO:009886910 | Endometrium | AEH | cellular oxidant detoxification | 26/2100 | 101/18723 | 3.57e-05 | 6.26e-04 | 26 |
GO:004545410 | Endometrium | AEH | cell redox homeostasis | 12/2100 | 35/18723 | 2.69e-04 | 3.12e-03 | 12 |
GO:00182086 | Endometrium | AEH | peptidyl-proline modification | 16/2100 | 58/18723 | 4.75e-04 | 4.91e-03 | 16 |
GO:009875410 | Endometrium | AEH | detoxification | 31/2100 | 152/18723 | 6.85e-04 | 6.62e-03 | 31 |
GO:00075482 | Endometrium | AEH | sex differentiation | 46/2100 | 276/18723 | 3.91e-03 | 2.64e-02 | 46 |
GO:00427439 | Endometrium | AEH | hydrogen peroxide metabolic process | 14/2100 | 58/18723 | 4.12e-03 | 2.73e-02 | 14 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRDX4 | SNV | Missense_Mutation | | c.785N>C | p.Gly262Ala | p.G262A | Q13162 | protein_coding | tolerated(0.22) | benign(0.018) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRDX4 | deletion | Frame_Shift_Del | novel | c.807delA | p.Lys269AsnfsTer2 | p.K269Nfs*2 | Q13162 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PRDX4 | SNV | Missense_Mutation | novel | c.665N>A | p.Gly222Asp | p.G222D | Q13162 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A7X5-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
PRDX4 | SNV | Missense_Mutation | | c.644N>T | p.Thr215Ile | p.T215I | Q13162 | protein_coding | deleterious(0) | possibly_damaging(0.798) | TCGA-A6-4105-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PRDX4 | SNV | Missense_Mutation | | c.804N>A | p.Asp268Glu | p.D268E | Q13162 | protein_coding | tolerated(1) | benign(0) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRDX4 | SNV | Missense_Mutation | novel | c.319N>T | p.Arg107Cys | p.R107C | Q13162 | protein_coding | deleterious(0) | possibly_damaging(0.882) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PRDX4 | SNV | Missense_Mutation | novel | c.194C>T | p.Ser65Phe | p.S65F | Q13162 | protein_coding | tolerated(0.09) | benign(0.001) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRDX4 | SNV | Missense_Mutation | novel | c.511C>T | p.Pro171Ser | p.P171S | Q13162 | protein_coding | tolerated(0.32) | benign(0.003) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRDX4 | SNV | Missense_Mutation | novel | c.8N>T | p.Ala3Val | p.A3V | Q13162 | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-AX-A3FT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRDX4 | SNV | Missense_Mutation | novel | c.319N>T | p.Arg107Cys | p.R107C | Q13162 | protein_coding | deleterious(0) | possibly_damaging(0.882) | TCGA-B5-A0JU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |